ARK Invest has purchased a large amount of shares of Ginkgo Bioworks.
Ginkgo Bioworks is a biotech venture company established in 2009 by researchers from MIT, aiming to commercialize "biofactories" that utilize genetically modified bacteria.
What Ginkgo aims to become in this field is like Amazon's AWS.
We aim to be a platform for various bio-ventures to launch their bio-tech businesses, specializing in bio factory businesses, with the goal of improving production efficiency and reducing production costs through automation.
What Ginkgo aims to become in this field is like Amazon's AWS.
We aim to be a platform for various bio-ventures to launch their bio-tech businesses, specializing in bio factory businesses, with the goal of improving production efficiency and reducing production costs through automation.
The range of applications for genetic engineering is wide, and Ginkgo provides a platform for multiple ventures that are striving to innovate in their respective business segments, offering a platform that allows for much cheaper production compared to creating their own bio factories.
As a business model, at present, the majority of the expenses are research facility fees, but in the future, the aim is to pursue capital gains through royalties from the resulting products and holding shares in partner companies.
As a business model, at present, the majority of the expenses are research facility fees, but in the future, the aim is to pursue capital gains through royalties from the resulting products and holding shares in partner companies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
秋葉原在住 上野恩賜公園を毎日ウォーキングした後、上野広小路のタリーズか御徒町春日通りのスタバで戦略を練る男
30Followers
54Following
80Visitors
Follow
アキバのヨッシー OP : Sojitz Corporation and GinkGobioWorks BioWorks have agreed to jointly develop Ginkgo's research and development services in the synthetic biology field within Japan, and have signed a business alliance agreement. Both companies aim to contribute to sustainable manufacturing by promoting the introduction of biomanufacturing utilizing synthetic biology to the Japanese manufacturing industry in the future.
The Japanese government has formulated a “biotechnology strategy” aiming to form a biotechnology-related market on a scale of 92 trillion yen as of 2030, and is working on the goal related to climate change to achieve carbon neutrality by 2050, and is promoting the use of biotechnology throughout the industry.
アキバのヨッシー OP : Ginkgo Bioworks Holdings, announced the acquisition of AgBiome's platform assets and the expansion of its strategic partnership with Novo Nordisk.
Ginkgo Bioworks says the assets acquired from AGBiome include over 115,000 sequenced and isolated strains, over 0.5 billion unique genetic sequences, and associated functional data and metadata.
Bringing AgBiome's incredible collection of strains and metagenomics to GinkGO will not only significantly expand its capabilities, but will also directly benefit Ginkgo customers in the agricultural biology field.
This makes it possible to improve the manufacture of Novonordisk drugs for severe chronic diseases, including diabetes and obesity drugs.
アキバのヨッシー OP : We have announced a partnership with Swiss company Syngenta aimed at promoting the development and commercialization of new biological solutions for agriculture.
By applying machine learning and data analysis, we aim to develop cost-effective microbial strains to release Syngenta products in a timely manner.
It can be expected to contribute to broader efforts to provide sustainable farming solutions to farmers around the world.
アキバのヨッシー OP : Institutional investors account for a large share of Ginkgo Bioworks and own 48% of the total. The involvement of institutional investors is supposed to indicate a certain level of trust in companies, and this contributes to the high number of shareholders.
Ginkgo Bioworks has attracted attention in the field of synthetic biology and has become a leader in this field. The potential of synthetic biology is attractive to many investors, and this has led to a large number of shareholders.
Ginkgo Bioworks also invests in hedge funds and private equity firms, and these investors anticipate medium- to long-term growth. In particular, strong investment motivation can also be seen from the fact that Baillie Gifford & Co., which is the largest shareholder, holds 12% of the shares.